PureTech Health (PTCHF) Stock Price, News & Analysis

Company Overview

PureTech Health PLC (“PureTech”) is a clinical-stage biopharmaceutical company focused on the development of innovative medicines to address serious diseases with high unmet medical need. Founded in 2005 by Daphne Zohar and headquartered in Boston, Massachusetts with operations in both North America and Europe, PureTech applies its proprietary platforms to advance therapeutic candidates across immunology, neuroscience and lymphatic-focused indications.

The company leverages three core technology platforms—immune tolerance, gut-targeted delivery and lymphatic transport—to develop novel molecules designed for enhanced specificity and durability of effect. PureTech’s pipeline includes deupirfenidone (LYT-100), a reformulated anti-fibrotic agent being evaluated in pulmonary disorders, and LYT-200, an immune-modulating antibody aimed at preventing post-surgical adhesions. In addition to its internal programs, PureTech has spun out multiple subsidiary companies, including Gelesis (weight-management therapies), Karuna Therapeutics (neuroscience) and Sonde Health (digital biomarkers).

PureTech’s business model emphasizes early-stage incubation, spin-out formation and selective alliances with large pharmaceutical companies to co-develop and commercialize promising assets. Research and development activities are conducted through in-house teams and collaborative networks, allowing the company to rapidly advance candidates from discovery through proof-of-concept clinical studies. This approach supports a diversified portfolio and offers multiple value-creation opportunities across different therapeutic areas.

Under the leadership of founder and Chief Executive Officer Daphne Zohar, PureTech Health continues to expand its global footprint and invest in next-generation platforms. The company’s multidisciplinary team of scientists, clinicians and business development professionals works across offices in the United States and Europe to translate cutting-edge science into potential new treatments for patients worldwide.

Key Stats

• Today's Range: $1.92 to $1.92
• 50-Day Range: $1.55 to $1.92
• 52-Week Range: $1.55 to $1.92
• Volume: N/A
• Average Volume: 47,696 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PTCHF Stock Analysis - Frequently Asked Questions

How have PTCHF shares performed this year?

PureTech Health's stock was trading at $1.7050 on January 1st, 2026. Since then, PTCHF stock has increased by 12.6% and is now trading at $1.92.

How do I buy shares of PureTech Health?

Shares of PTCHF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:PTCHF
• CIK: 1782999
• Web: www.puretechhealth.com
• Phone: (617) 482-2333
• Fax: N/A
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A